Mitomycin-C Induced Hemolytic Uremic Syndrome: A Case Report and Literature Review

Dou Chen Wu, Jacqueline Ming Liu, Yuh Min Chen, Shuling Yang, Shian Min Liu, Li Tzong Chen, Jacqueline Whang-Peng

研究成果: 雜誌貢獻文章同行評審

21 引文 斯高帕斯(Scopus)


Hemolytic uremic syndrome spontaneously arises in a few patients with advanced cancer, but it is more commonly related to the use of certain chemotherapeutic agents. Mitomycin-C is, etiologically, the most common causative agent inducing hemolytic uremic syndrome, in a dose dependent manner. We report this syndrome, attributable to mitomycin-C at a cumulative dose of 40 mg/m2, in a gastric cancer patient. A 42-year-old female with stage III gastric cancer underwent radical gastrectomy and was given mitomycin-C at 10 mg/m2 intravenously every four weeks as adjuvant therapy. Hemolytic uremic syndrome was diagnosed three months after the last dose of mitomycin-C administration. The most prominent symptoms included pallor, hypertension and anasarca, with laboratory evidence of microangiopathic hemolytic anemia, azotemia and hyperkalemia. Her disease was progressive, but fortunately stabilized after staphylococcus column A dialysis. Her disease remained in remission for 24 months from the time of diagnosis, and then relapsed in the form of peritoneal carcinomatosis with partial intestinal obstruction.
頁(從 - 到)115-118
期刊Japanese Journal of Clinical Oncology
出版狀態已發佈 - 12月 1 1997

ASJC Scopus subject areas

  • 腫瘤科
  • 放射學、核子醫學和影像學
  • 癌症研究


深入研究「Mitomycin-C Induced Hemolytic Uremic Syndrome: A Case Report and Literature Review」主題。共同形成了獨特的指紋。